Shell Asset Management Co. lessened its holdings in Bruker Co. (NASDAQ:BRKR – Get Rating) by 17.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,759 shares of the medical research company’s stock after selling 1,844 shares during the period. Shell Asset Management Co.’s holdings in Bruker were worth $599,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of BRKR. Wipfli Financial Advisors LLC acquired a new stake in shares of Bruker in the third quarter worth approximately $25,000. Zions Bancorporation N.A. purchased a new position in shares of Bruker in the 1st quarter valued at $26,000. Ronald Blue Trust Inc. lifted its holdings in shares of Bruker by 59.2% during the 3rd quarter. Ronald Blue Trust Inc. now owns 764 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 284 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Bruker in the third quarter worth about $57,000. Finally, Covestor Ltd grew its stake in shares of Bruker by 165.8% in the first quarter. Covestor Ltd now owns 1,321 shares of the medical research company’s stock valued at $85,000 after buying an additional 824 shares in the last quarter. 70.40% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, CEO Frank H. Laukien sold 16,435 shares of the firm’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $79.21, for a total transaction of $1,301,816.35. Following the completion of the transaction, the chief executive officer now owns 38,352,034 shares of the company’s stock, valued at $3,037,864,613.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Bruker news, CEO Frank H. Laukien sold 16,435 shares of Bruker stock in a transaction that occurred on Wednesday, May 3rd. The shares were sold at an average price of $79.21, for a total value of $1,301,816.35. Following the transaction, the chief executive officer now owns 38,352,034 shares in the company, valued at $3,037,864,613.14. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Frank H. Laukien sold 82,795 shares of the stock in a transaction on Monday, May 1st. The shares were sold at an average price of $78.75, for a total value of $6,520,106.25. Following the completion of the transaction, the chief executive officer now owns 38,262,287 shares of the company’s stock, valued at approximately $3,013,155,101.25. The disclosure for this sale can be found here. Insiders sold 247,460 shares of company stock worth $19,831,517 over the last ninety days. Company insiders own 27.60% of the company’s stock.
Bruker Stock Performance
Bruker (NASDAQ:BRKR – Get Rating) last posted its earnings results on Thursday, February 9th. The medical research company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.72 by $0.02. The firm had revenue of $708.40 million for the quarter, compared to analysts’ expectations of $697.68 million. Bruker had a return on equity of 34.13% and a net margin of 11.72%. The firm’s revenue was up 3.6% compared to the same quarter last year. During the same period last year, the firm earned $0.59 EPS. As a group, equities analysts anticipate that Bruker Co. will post 2.55 earnings per share for the current year.
Bruker Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 17th. Investors of record on Wednesday, March 1st were paid a dividend of $0.05 per share. The ex-dividend date was Tuesday, February 28th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.25%. Bruker’s dividend payout ratio is presently 10.05%.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on BRKR shares. StockNews.com lowered shares of Bruker from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Citigroup upped their target price on Bruker from $80.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, February 10th. Finally, The Goldman Sachs Group lifted their price target on shares of Bruker from $63.00 to $70.00 and gave the stock a “sell” rating in a research note on Wednesday, April 19th. One research analyst has rated the stock with a sell rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Bruker has a consensus rating of “Moderate Buy” and a consensus price target of $76.25.
About Bruker
Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST).
Featured Stories
- Get a free copy of the StockNews.com research report on Bruker (BRKR)
- Apple Crushes; Get Ready For All-Time Highs
- Investors Are Barking Up The Right Tree With Datadog
- How to Invest in Central Bank Digital Currency
- Kellogg Company Looks GRRR-eat! At These Levels
- PacWest, First Horizon Shares Plummet On Continued Bank Worries
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.
